Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Turning Point Therapeutics, Inc. (TPTX) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Turning Point Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1595893.
Total stock buying since 2019: $60,006,240.
Total stock sales since 2019: $71,320,443.
Total stock option exercises since 2019: $6,301,703.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2022 | 0 | $0 | 6,110 | $267,502 | 0 | $0 |
| 2021 | 0 | $0 | 267,392 | $31,192,845 | 268,305 | $5,728,269 |
| 2020 | 170,832 | $10,249,920 | 493,500 | $26,447,372 | 0 | $0 |
| 2019 | 2,212,576 | $49,756,320 | 243,000 | $13,412,724 | 132,432 | $573,434 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2022-07 | 0 | $0 | 1,183 | $88,654 | 0 | $0 |
| 2022-02 | 0 | $0 | 4,927 | $178,848 | 0 | $0 |
| 2021-08 | 0 | $0 | 10,000 | $800,000 | 10,000 | $170,000 |
| 2021-07 | 0 | $0 | 1,869 | $139,988 | 0 | $0 |
| 2021-06 | 0 | $0 | 15,000 | $1,155,645 | 15,000 | $255,000 |
| 2021-05 | 0 | $0 | 0 | $0 | 5,882 | $99,994 |
| 2021-03 | 0 | $0 | 83,985 | $8,837,282 | 83,985 | $2,290,534 |
| 2021-02 | 0 | $0 | 115,000 | $15,200,957 | 115,000 | $2,237,898 |
| 2021-01 | 0 | $0 | 41,538 | $5,058,973 | 38,438 | $674,843 |
| 2020-06 | 0 | $0 | 65,000 | $4,199,570 | 0 | $0 |
| 2020-05 | 170,832 | $10,249,920 | 88,000 | $4,819,764 | 0 | $0 |
| 2020-04 | 0 | $0 | 88,708 | $4,168,014 | 0 | $0 |
| 2020-03 | 0 | $0 | 87,292 | $3,730,905 | 0 | $0 |
| 2020-02 | 0 | $0 | 76,500 | $4,665,534 | 0 | $0 |
| 2020-01 | 0 | $0 | 88,000 | $4,863,585 | 0 | $0 |
| 2019-12 | 0 | $0 | 243,000 | $13,412,724 | 54,944 | $244,755 |
| 2019-09 | 367,776 | $16,549,920 | 0 | $0 | 0 | $0 |
| 2019-06 | 0 | $0 | 0 | $0 | 54,220 | $277,606 |
| 2019-05 | 0 | $0 | 0 | $0 | 23,268 | $51,073 |
| 2019-04 | 1,844,800 | $33,206,400 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-07-27 | Tombesi Paolo (EVP & Chief Financial Officer) | Sale | 1,183 | 74.94 | 88,654 |
| 2022-02-09 | Partridge Andrew John (EVP & Chief Commercial Officer) | Sale | 221 | 36.30 | 8,022 |
| 2022-02-09 | Hirmand Mohammad (EVP & Chief Medical Officer) | Sale | 669 | 36.30 | 24,284 |
| 2022-02-09 | Countouriotis Athena (President & CEO) | Sale | 2,971 | 36.30 | 107,847 |
| 2022-02-09 | Reich Siegfried (EVP & Chief Scientific Officer) | Sale | 397 | 36.30 | 14,411 |
| 2022-02-09 | North Annette (EVP & General Counsel) | Sale | 669 | 36.30 | 24,284 |
| 2021-08-30 | North Annette (EVP, General Counsel & Secty.) | Sale | 10,000 | 80.00 | 800,000 |
| 2021-08-30 | North Annette (EVP, General Counsel & Secty.) | Option Ex | 10,000 | 17.00 | 170,000 |
| 2021-07-14 | Partridge Andrew John (EVP & Chief Commercial Officer) | Sale | 1,869 | 74.90 | 139,988 |
| 2021-06-15 | North Annette (EVP, General Counsel & Secty.) | Sale | 15,000 | 77.04 | 1,155,645 |
| 2021-06-15 | North Annette (EVP, General Counsel & Secty.) | Option Ex | 15,000 | 17.00 | 255,000 |
| 2021-05-06 | North Annette (EVP, General Counsel & Secty.) | Option Ex | 5,882 | 17.00 | 99,994 |
| 2021-03-23 | Baker Brian Lee (SVP of Finance and Admin.) | Sale | 28,435 | 100.99 | 2,871,679 |
| 2021-03-23 | Baker Brian Lee (SVP of Finance and Admin.) | Option Ex | 28,435 | 4.49 | 127,530 |
| 2021-03-08 | North Annette (EVP, General Counsel & Secty.) | Sale | 20,000 | 108.95 | 2,178,960 |
| 2021-03-08 | North Annette (EVP, General Counsel & Secty.) | Option Ex | 20,000 | 17.00 | 340,000 |
| 2021-03-04 | Reich Siegfried (EVP & Chief Scientific Officer) | Sale | 35,550 | 106.52 | 3,786,643 |
| 2021-03-04 | Reich Siegfried (EVP & Chief Scientific Officer) | Option Ex | 35,550 | 51.28 | 1,823,004 |
| 2021-02-11 | Countouriotis Athena (President & CEO) | Sale | 8,942 | 137.55 | 1,229,998 |
| 2021-02-11 | Countouriotis Athena (President & CEO) | Option Ex | 8,942 | 3.20 | 28,614 |
| 2021-02-10 | Countouriotis Athena (President & CEO) | Sale | 25,392 | 136.43 | 3,464,128 |
| 2021-02-10 | Countouriotis Athena (President & CEO) | Option Ex | 25,392 | 3.20 | 81,254 |
| 2021-02-09 | Countouriotis Athena (President & CEO) | Sale | 25,666 | 138.49 | 3,554,535 |
| 2021-02-09 | Countouriotis Athena (President & CEO) | Option Ex | 25,666 | 3.20 | 82,131 |
| 2021-02-02 | Larson Yi (EVP & Chief Financial Officer) | Sale | 14,298 | 129.62 | 1,853,306 |
| 2021-02-02 | Larson Yi (EVP & Chief Financial Officer) | Option Ex | 14,298 | 54.03 | 772,520 |
| 2021-02-02 | North Annette (EVP, General Counsel & Secty.) | Sale | 9,016 | 129.25 | 1,165,336 |
| 2021-02-02 | North Annette (EVP, General Counsel & Secty.) | Option Ex | 9,016 | 17.00 | 153,272 |
| 2021-02-01 | Larson Yi (EVP & Chief Financial Officer) | Sale | 15,702 | 124.33 | 1,952,198 |
| 2021-02-01 | Larson Yi (EVP & Chief Financial Officer) | Option Ex | 15,702 | 54.03 | 848,379 |
| 2021-02-01 | North Annette (EVP, General Counsel & Secty.) | Sale | 15,984 | 123.97 | 1,981,456 |
| 2021-02-01 | North Annette (EVP, General Counsel & Secty.) | Option Ex | 15,984 | 17.00 | 271,728 |
| 2021-01-07 | Baker Brian Lee (SVP of Finance and Admin.) | Sale | 31,238 | 121.97 | 3,810,036 |
| 2021-01-07 | Baker Brian Lee (SVP of Finance and Admin.) | Option Ex | 28,438 | 4.49 | 127,544 |
| 2021-01-05 | Hirmand Mohammad (EVP and Chief Medical Officer) | Sale | 1,253 | 120.00 | 150,360 |
| 2021-01-05 | Hirmand Mohammad (EVP and Chief Medical Officer) | Option Ex | 1,253 | 54.73 | 68,576 |
| 2021-01-04 | Hirmand Mohammad (EVP and Chief Medical Officer) | Sale | 9,047 | 121.43 | 1,098,577 |
| 2021-01-04 | Hirmand Mohammad (EVP and Chief Medical Officer) | Option Ex | 8,747 | 54.73 | 478,723 |
| 2020-06-09 | Cui Jingrong Jean (Director) | Sale | 9,500 | 65.70 | 624,150 |
| 2020-06-08 | Cui Jingrong Jean (Director) | Sale | 18,500 | 63.26 | 1,170,310 |
| 2020-06-05 | Cui Jingrong Jean (Director) | Sale | 18,500 | 64.44 | 1,192,195 |
| 2020-06-04 | Cui Jingrong Jean (Director) | Sale | 18,500 | 65.56 | 1,212,915 |
| 2020-05-21 | Cui Jingrong Jean (Director) | Sale | 7,000 | 59.99 | 419,930 |
| 2020-05-21 | George Simeon (Director) | Buy | 83,333 | 60.00 | 4,999,980 |
| 2020-05-21 | Countouriotis Athena (President & CEO) | Buy | 4,166 | 60.00 | 249,960 |
| 2020-05-21 | Glaxosmithkline Plc | Buy | 83,333 | 60.00 | 4,999,980 |
| 2020-05-20 | Cui Jingrong Jean (Director) | Sale | 7,000 | 60.02 | 420,119 |
| 2020-05-19 | Cui Jingrong Jean (Director) | Sale | 7,000 | 57.77 | 404,376 |
| 2020-05-08 | Cui Jingrong Jean (Director) | Sale | 11,500 | 53.92 | 620,057 |
| 2020-05-07 | Cui Jingrong Jean (Director) | Sale | 18,500 | 52.99 | 980,315 |
| 2020-05-06 | Cui Jingrong Jean (Director) | Sale | 18,500 | 52.84 | 977,447 |
| 2020-05-05 | Cui Jingrong Jean (Director) | Sale | 18,500 | 53.92 | 997,520 |
| 2020-04-24 | Cui Jingrong Jean (Director) | Sale | 7,000 | 51.30 | 359,079 |
| 2020-04-23 | Cui Jingrong Jean (Director) | Sale | 7,000 | 52.55 | 367,885 |
| 2020-04-22 | Cui Jingrong Jean (Director) | Sale | 7,000 | 52.02 | 364,175 |
| 2020-04-13 | Cui Jingrong Jean (Director) | Sale | 708 | 49.84 | 35,288 |
| 2020-04-09 | Cui Jingrong Jean (Director) | Sale | 11,500 | 47.79 | 549,619 |
| 2020-04-08 | Cui Jingrong Jean (Director) | Sale | 18,500 | 46.51 | 860,490 |
| 2020-04-07 | Cui Jingrong Jean (Director) | Sale | 18,500 | 44.76 | 828,060 |
| 2020-04-06 | Cui Jingrong Jean (Director) | Sale | 18,500 | 43.43 | 803,418 |
| 2020-03-26 | Cui Jingrong Jean (Director) | Sale | 11,500 | 46.87 | 538,947 |
| 2020-03-25 | Cui Jingrong Jean (Director) | Sale | 17,792 | 45.88 | 816,296 |
| 2020-03-24 | Cui Jingrong Jean (Director) | Sale | 7,000 | 42.20 | 295,365 |
| 2020-03-23 | Cui Jingrong Jean (Director) | Sale | 7,000 | 38.20 | 267,400 |
| 2020-03-12 | Cui Jingrong Jean (Director) | Sale | 7,000 | 36.47 | 255,290 |
| 2020-03-11 | Cui Jingrong Jean (Director) | Sale | 18,500 | 41.74 | 772,227 |
| 2020-03-10 | Cui Jingrong Jean (Director) | Sale | 18,500 | 42.45 | 785,380 |
| 2020-02-26 | Cui Jingrong Jean (Director) | Sale | 7,000 | 51.84 | 362,880 |
| 2020-02-25 | Cui Jingrong Jean (Director) | Sale | 7,000 | 52.00 | 364,000 |
| 2020-02-24 | Cui Jingrong Jean (Director) | Sale | 7,000 | 53.91 | 377,405 |
| 2020-02-12 | Cui Jingrong Jean (Director) | Sale | 18,500 | 66.10 | 1,222,850 |
| 2020-02-11 | Cui Jingrong Jean (Director) | Sale | 18,500 | 63.45 | 1,173,917 |
| 2020-02-10 | Cui Jingrong Jean (Director) | Sale | 18,500 | 62.95 | 1,164,482 |
| 2020-01-29 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 7,000 | 59.05 | 413,329 |
| 2020-01-28 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 7,000 | 58.40 | 408,779 |
| 2020-01-27 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 7,000 | 57.64 | 403,501 |
| 2020-01-15 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 11,500 | 53.34 | 613,467 |
| 2020-01-14 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 18,500 | 53.27 | 985,439 |
| 2020-01-13 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 18,500 | 53.27 | 985,495 |
| 2020-01-10 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 18,500 | 56.95 | 1,053,575 |
| 2019-12-30 | Cui Jingrong Jean (Director) | Option Ex | 16,864 | 5.12 | 86,343 |
| 2019-12-27 | Cui Jingrong Jean (Director) | Option Ex | 38,080 | 4.16 | 158,412 |
| 2019-12-20 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 11,500 | 63.35 | 728,525 |
| 2019-12-19 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 18,500 | 61.09 | 1,130,072 |
| 2019-12-18 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 18,500 | 59.10 | 1,093,350 |
| 2019-12-17 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 18,500 | 61.55 | 1,138,638 |
| 2019-12-16 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 11,500 | 58.14 | 668,575 |
| 2019-12-13 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 11,500 | 56.18 | 646,104 |
| 2019-12-12 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 11,500 | 54.00 | 620,965 |
| 2019-12-11 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 11,500 | 53.53 | 615,595 |
| 2019-12-10 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 11,500 | 54.70 | 629,084 |
| 2019-12-09 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 11,500 | 55.60 | 639,400 |
| 2019-12-06 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 50,890 | 50.84 | 2,587,502 |
| 2019-12-05 | Cui Jingrong Jean (Chief Scientific Officer) | Sale | 56,110 | 51.95 | 2,914,914 |
| 2019-09-10 | Larson Yi (EVP & Chief Financial Officer) | Buy | 2,222 | 45.00 | 99,990 |
| 2019-09-10 | George Simeon (Director) | Buy | 177,777 | 45.00 | 7,999,965 |
| 2019-09-10 | Countouriotis Athena (President & CEO) | Buy | 10,000 | 45.00 | 450,000 |
| 2019-09-10 | Glaxosmithkline Plc | Buy | 177,777 | 45.00 | 7,999,965 |
| 2019-06-27 | Cui Jingrong Jean (Director) | Option Ex | 54,220 | 5.12 | 277,606 |
| 2019-05-14 | Chen Bihua | Option Ex | 23,268 | 2.19 | 51,073 |
| 2019-04-22 | Baker Brian Lee (VP of Finance and Admin.) | Buy | 2,800 | 18.00 | 50,400 |
| 2019-04-22 | Lu Hongbo (Director) | Buy | 60,000 | 18.00 | 1,080,000 |
| 2019-04-22 | Orbimed Capital Gp Vi Llc (Director) | Buy | 360,000 | 18.00 | 6,480,000 |
| 2019-04-22 | Chen Bihua | Buy | 400,000 | 18.00 | 7,200,000 |
| 2019-04-22 | George Simeon (Director) | Buy | 325,000 | 18.00 | 5,850,000 |
| 2019-04-22 | Countouriotis Athena (President & CEO) | Buy | 12,000 | 18.00 | 216,000 |
| 2019-04-22 | Gordon Carl L (Director) | Buy | 360,000 | 18.00 | 6,480,000 |
| 2019-04-22 | Glaxosmithkline Plc | Buy | 325,000 | 18.00 | 5,850,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of TPTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Turning Point Therapeutics, Inc. (symbol TPTX, CIK number 1595893) see the Securities and Exchange Commission (SEC) website.